Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug deliveryPoly(lactic acid)/poly(lactic‑co‑glycolic acid) particulate carriers for pulmonary drug delivery
- Authors
- Emami, F.; Mostafavi Yazdi, S.J.; Na, D.H.
- Issue Date
- 1-Jul-2019
- Publisher
- Springer Netherlands
- Keywords
- Microparticles; Nanoparticles; Poly(lactic acid); Poly(lactic-co-glycolic acid); Pulmonary drug delivery
- Citation
- Journal of Pharmaceutical Investigation, v.49, no.4, pp 427 - 442
- Pages
- 16
- Journal Title
- Journal of Pharmaceutical Investigation
- Volume
- 49
- Number
- 4
- Start Page
- 427
- End Page
- 442
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/26335
- DOI
- 10.1007/s40005-019-00443-1
- ISSN
- 2093-5552
2093-6214
- Abstract
- Background: Pulmonary route is an attractive target for both systemic and local drug delivery, with the advantages of a large surface area, rich blood supply, and absence of first-pass metabolism. Numerous polymeric micro/nanoparticles have been designed and studied for controlled and targeted drug delivery to the lung. Area covered: Among the natural and synthetic polymers for polymeric particles, poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) have been widely used for the delivery of anti-cancer agents, anti-inflammatory drugs, vaccines, peptides, and proteins because of their highly biocompatible and biodegradable properties. This review focuses on the characteristics of PLA/PLGA particles as carriers of drugs for efficient delivery to the lung. Furthermore, the manufacturing techniques of the polymeric particles, and their applications for inhalation therapy were discussed. Expert opinion: Compared to other carriers including liposomes, PLA/PLGA particles present a high structural integrity providing enhanced stability, higher drug loading, and prolonged drug release. Adequately designed and engineered polymeric particles can contribute to a desirable pulmonary drug delivery characterized by a sustained drug release, prolonged drug action, reduction in the therapeutic dose, and improved patient compliance. © 2019, The Korean Society of Pharmaceutical Sciences and Technology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.